Ting Zhou

天津医科大学

H指数:14

被引数:850

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health utility book: A systematic review and meta-analysis of health utilities in gastric cancer

健康效用手册：胃癌健康效用的系统评价和荟萃分析

Supportive Care in Cancer

IF3

2025-10-040

PRE

Arachidonic acid fuels inflammation by unlocking macrophage protein phosphatase 5 after myocardial infarction

花生四烯酸通过在心肌梗死后激活巨噬细胞蛋白磷酸酶5来促进炎症。

EUROPEAN HEART JOURNAL

IF35.6

2025-09-011

PRE

Economic burden and influence factors among hospitalized children with bronchiolitis or pneumonia: a multiregional study in China

中国毛细支气管炎或肺炎住院患儿经济负担及影响因素的多区域研究

FRONTIERS IN PUBLIC HEALTH

IF3.4

2024-09-021

OAAI

Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system

CNS NEUROSCIENCE & THERAPEUTICS

IF5

2024-07-150

OAAI

The causal relationship between metabolic syndrome and its components and cardiovascular disease: A mendelian randomization study

代谢综合征及其组分与心血管疾病的因果关系: 孟德尔随机化研究

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2024-05-012

PRE

Risk factors for acute kidney injury in COVID-19 patients: an updated systematic review and meta-analysis

新型冠状病毒肺炎患者急性肾损伤的危险因素: 最新的系统评价和荟萃分析

RENAL FAILURE

IF3

2023-04-0622

OAAI

Sponsorship bias in oncology cost effectiveness analysis

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2023-04-016

PRE

Multi-assessment of critical steno-occlusive middle cerebral arteries: transcranial Doppler combined with magnetic resonance angiography

HELIYON

IF3.6

2022-10-012

OAAI

Industry sponsorship bias in cost effectiveness analysis: registry based analysis

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2022-06-2227

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China

FRONTIERS IN PUBLIC HEALTH

IF3.4

2022-03-3112

OAAI

Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma

ADVANCES IN THERAPY

IF4

2022-03-1619

PRE

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naive Patients With Moderate-to-Severe Ulcerative Colitis in China

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-08-209

OAAI

EQ-5D-5L测量不同疾病患者健康相关生活质量的系统评价

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-06-29108

OAAI

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China

维多珠单抗治疗中国中重度克罗恩病的成本-效果分析

ADVANCES IN THERAPY

IF4

2021-06-056

OAAI

Economic Burden of Major Diseases in China in 2013

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-05-199

OAAI

Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease

MEDICAL DECISION MAKING

IF2.3

2021-04-036

OAAI

IMPACT OF PATIENT-TARGETED FINANCIAL INCENTIVES ON HEALTHCARE COSTS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS

VALUE IN HEALTH

IF6

2019-05-010

OAAI

THE COMPARISON BETWEEN LEAD-TIME AND LAG-TIME TTO IN CHINA, NANJING

VALUE IN HEALTH

IF6

2018-09-010

OAAI

The quality of life in Chinese population with chronic non-communicable diseases according to EQ-5D-3L: a systematic review

QUALITY OF LIFE RESEARCH

IF2.7

2018-07-0666

OAAI

THE COST-EFFECTIVENESS ANALYSIS OF SHENFU INJECTION COMBINED WITH CONVENTIONAL THERAPY FOR HEART FAILURE PATIENTS IN CHINA

VALUE IN HEALTH

IF6

2018-05-010

OAAI

Ting Zhou

个人简介

教育背景

工作经历

荣誉奖项

研究方向